XML 15 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Operating activities:    
Net loss $ (93,128,000) $ (76,671,000)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 16,171,000 11,186,000
Depreciation and amortization 741,000 489,000
Amortization of debt discount 374,000 336,000
Loss on disposal of property and equipment 5,000
(Accretion of discount) amortization of premium on short-term investments (168,000) 196,000
Change in operating assets and liabilities:    
Accounts receivable (16,656,000)
Prepaid expenses and other current assets 32,000 325,000
Inventory 539,000 (3,312,000)
Accounts payable (499,000) 5,361,000
Accrued clinical liabilities 1,209,000 4,254,000
Accrued payroll and employee liabilities (1,156,000) (154,000)
Deferred revenue 3,689,000
Other accrued liabilities 6,236,000 (1,471,000)
Net cash used for operating activities (82,611,000) (59,461,000)
Investing activities:    
Purchases of short-term investments (93,776,000)
Maturities and sales of short-term investments 52,693,000 43,129,000
Purchases of property and equipment (1,424,000) (1,911,000)
Net cash (used for) provided by investing activities (42,507,000) 41,218,000
Financing activities:    
Net proceeds from sale of common stock 163,747,000
Repayment of promissory note payable (25,000,000)
Proceeds from purchases under the Employee Stock Purchase Plan 576,000 251,000
Proceeds from stock option exercises 2,658,000 4,755,000
Net cash provided by financing activities 141,981,000 5,006,000
Net increase (decrease) in cash and cash equivalents 16,863,000 (13,237,000)
Cash and cash equivalents at beginning of year 13,414,000 75,180,000
Cash and cash equivalents at end of period 30,277,000 61,943,000
Supplemental disclosure of cash flow information:    
Interest paid $ 1,789,000